Abstract
Introduction: Cytomegalovirus (CMV) still causes significant morbidity and mortality in patients given allogeneic hematopoietic stem cell transplantation (HSCT). Despite effective pharmacotherapy, potentially life-threatening CMV disease occurs nowadays in up to 10% of HSCT recipients; moreover, routinely used anti-CMV agents have been shown to be associated with morbidity. Areas covered: This review examines different issues related to diagnosis and management of CMV infection in HSCT recipients, paying particular attention to the monitoring of CMV-specific immune recovery, approaches of adoptive cell therapy and new antiviral drugs. Expert commentary: Despite advances in diagnostic tests and treatment, there is still room for refining management of CMV in HSCT recipients. Immunological monitoring should be associated in the future to virological monitoring. The safety profile and efficacy of new anti-CMV agents should be compared with that of standard-of-care drugs. Donor-derived, pathogen-specific T cells adoptively transferred after transplantation could contribute to reduce the impact of CMV infection on patient’s outcome.
| Original language | English |
|---|---|
| Pages (from-to) | 1093-1105 |
| Number of pages | 13 |
| Journal | Expert Review of Hematology |
| Volume | 9 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - Nov 1 2016 |
Fingerprint
Keywords
- adoptive T-cell therapy
- anti-viral drugs
- CMV infection
- CMV vaccines
- generation of CMV-specific T cells
- immune monitoring
- monitoring of CMV viral load
ASJC Scopus subject areas
- Hematology
Cite this
Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection. / Locatelli, Franco; Bertaina, Alice; Bertaina, Valentina; Merli, Pietro.
In: Expert Review of Hematology, Vol. 9, No. 11, 01.11.2016, p. 1093-1105.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Cytomegalovirus in hematopoietic stem cell transplant recipients - management of infection
AU - Locatelli, Franco
AU - Bertaina, Alice
AU - Bertaina, Valentina
AU - Merli, Pietro
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Introduction: Cytomegalovirus (CMV) still causes significant morbidity and mortality in patients given allogeneic hematopoietic stem cell transplantation (HSCT). Despite effective pharmacotherapy, potentially life-threatening CMV disease occurs nowadays in up to 10% of HSCT recipients; moreover, routinely used anti-CMV agents have been shown to be associated with morbidity. Areas covered: This review examines different issues related to diagnosis and management of CMV infection in HSCT recipients, paying particular attention to the monitoring of CMV-specific immune recovery, approaches of adoptive cell therapy and new antiviral drugs. Expert commentary: Despite advances in diagnostic tests and treatment, there is still room for refining management of CMV in HSCT recipients. Immunological monitoring should be associated in the future to virological monitoring. The safety profile and efficacy of new anti-CMV agents should be compared with that of standard-of-care drugs. Donor-derived, pathogen-specific T cells adoptively transferred after transplantation could contribute to reduce the impact of CMV infection on patient’s outcome.
AB - Introduction: Cytomegalovirus (CMV) still causes significant morbidity and mortality in patients given allogeneic hematopoietic stem cell transplantation (HSCT). Despite effective pharmacotherapy, potentially life-threatening CMV disease occurs nowadays in up to 10% of HSCT recipients; moreover, routinely used anti-CMV agents have been shown to be associated with morbidity. Areas covered: This review examines different issues related to diagnosis and management of CMV infection in HSCT recipients, paying particular attention to the monitoring of CMV-specific immune recovery, approaches of adoptive cell therapy and new antiviral drugs. Expert commentary: Despite advances in diagnostic tests and treatment, there is still room for refining management of CMV in HSCT recipients. Immunological monitoring should be associated in the future to virological monitoring. The safety profile and efficacy of new anti-CMV agents should be compared with that of standard-of-care drugs. Donor-derived, pathogen-specific T cells adoptively transferred after transplantation could contribute to reduce the impact of CMV infection on patient’s outcome.
KW - adoptive T-cell therapy
KW - anti-viral drugs
KW - CMV infection
KW - CMV vaccines
KW - generation of CMV-specific T cells
KW - immune monitoring
KW - monitoring of CMV viral load
UR - http://www.scopus.com/inward/record.url?scp=84994021773&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994021773&partnerID=8YFLogxK
U2 - 10.1080/17474086.2016.1242406
DO - 10.1080/17474086.2016.1242406
M3 - Review article
AN - SCOPUS:84994021773
VL - 9
SP - 1093
EP - 1105
JO - Expert Review of Hematology
JF - Expert Review of Hematology
SN - 1747-4086
IS - 11
ER -